US6770283B1
(en)
*
|
1990-12-13 |
2004-08-03 |
Bioption Ab |
DNA expression systems based on alphaviruses
|
US6015686A
(en)
*
|
1993-09-15 |
2000-01-18 |
Chiron Viagene, Inc. |
Eukaryotic layered vector initiation systems
|
ES2328424T3
(es)
*
|
1993-09-15 |
2009-11-12 |
Novartis Vaccines And Diagnostics, Inc. |
Vectores de alfavirus recombinantes.
|
SE9401091D0
(sv)
|
1994-03-31 |
1994-03-31 |
Bioption Ab |
Alphavirus cDNA vectors
|
SE9401709D0
(sv)
|
1994-05-18 |
1994-05-18 |
Mathilda Sjoeberg |
Improved alphavirus vectors for expression of heterologous DNA
|
US5505947A
(en)
*
|
1994-05-27 |
1996-04-09 |
The University Of North Carolina At Chapel Hill |
Attenuating mutations in Venezuelan Equine Encephalitis virus
|
DE19512142A1
(de)
*
|
1995-03-31 |
1996-10-02 |
Immuno Ag |
Infektiöser cDNA-Klon des Tick-Borne Enzephalitis (TBE)-Virus, davon abgeleiteter rekombinanter Impfstoff und Herstellung desselben sowie ein pharmazeutisches Produkt, das eine replizierbare Nukleinsäure enthält
|
US5792462A
(en)
*
|
1995-05-23 |
1998-08-11 |
University Of North Carolina At Chapel Hill |
Alphavirus RNA replicon systems
|
US5639650A
(en)
*
|
1995-05-23 |
1997-06-17 |
The University Of North Carolina At Chapel Hill |
cDNA clone for South African Arbovirus No. 86
|
US6451592B1
(en)
|
1996-04-05 |
2002-09-17 |
Chiron Corporation |
Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
|
US6458560B1
(en)
|
1996-04-05 |
2002-10-01 |
Chiron Corporation |
Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
|
US5677124A
(en)
*
|
1996-07-03 |
1997-10-14 |
Ambion, Inc. |
Ribonuclease resistant viral RNA standards
|
US5939262A
(en)
|
1996-07-03 |
1999-08-17 |
Ambion, Inc. |
Ribonuclease resistant RNA preparation and utilization
|
US6489167B1
(en)
|
1996-09-25 |
2002-12-03 |
The Government Of The United States As Represented By The Secretary Of The Department Of Human Services |
Retroviral packaging cassettes amplified in the cytoplasm by autocatalytic Togavirus vectors
|
AU729690B2
(en)
*
|
1996-10-10 |
2001-02-08 |
Henrik Garoff |
Alphavirus-retrovirus vectors
|
US6544523B1
(en)
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
US5811407A
(en)
|
1997-02-19 |
1998-09-22 |
The University Of North Carolina At Chapel Hill |
System for the in vivo delivery and expression of heterologous genes in the bone marrow
|
US6432699B1
(en)
*
|
1997-03-28 |
2002-08-13 |
New York University |
Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
|
WO1999019466A2
(en)
|
1997-10-14 |
1999-04-22 |
Darwin Molecular Corporation |
Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
|
EP1900818A3
(en)
|
1997-11-06 |
2008-06-11 |
Novartis Vaccines and Diagnostics S.r.l. |
Neisserial antigens
|
US20030180257A1
(en)
|
1997-11-14 |
2003-09-25 |
Mark Parrington |
Alphavirus vectors for paramyxovirus vaccines
|
AU1979599A
(en)
|
1998-01-14 |
1999-08-02 |
Chiron S.P.A. |
(neisseria meningitidis) antigens
|
EP1069908B1
(en)
|
1998-04-08 |
2010-02-10 |
The University of North Carolina at Chapel Hill |
Cancer vaccine comprising alphavirus replicon particles
|
US6844188B1
(en)
|
1998-04-08 |
2005-01-18 |
University Of North Carolina At Chapel Hill |
Methods and modified cells for the treatment of cancer
|
EP2261356A3
(en)
|
1998-05-01 |
2012-01-04 |
Novartis Vaccines and Diagnostics, Inc. |
Neisseria meningitidis antigens and compositions
|
ATE369429T1
(de)
*
|
1998-05-08 |
2007-08-15 |
Intervet Int Bv |
Strukturproteine des virus, welches die pankreas- krankheit bei fischen verursacht, und ihre verwendungen
|
DE69938190T2
(de)
|
1998-10-15 |
2009-03-05 |
Novartis Vaccines and Diagnostics, Inc., Emeryville |
Gene mit veränderter expression in metastatischen brust- oder dickdarm- krebszellen
|
CA2354183A1
(en)
*
|
1998-11-30 |
2000-06-08 |
Cytos Biotechnology Ag |
Ordered molecular presentation of antigens, method of preparation and use
|
PT1141331E
(pt)
|
1998-12-16 |
2008-12-22 |
Novartis Vaccines & Diagnostic |
Quinase dependente de ciclina humana (hpnqalre)
|
JP4637368B2
(ja)
|
1999-04-14 |
2011-02-23 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
アルファウイルスに基づくベクター系を利用する免疫応答を生成するための組成物および方法
|
US8647864B2
(en)
*
|
1999-04-14 |
2014-02-11 |
Novartis Ag |
Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
|
CA2372235A1
(en)
|
1999-04-30 |
2000-11-09 |
Rino Rappuoli |
Conserved neisserial antigens
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
US6297013B1
(en)
|
1999-06-24 |
2001-10-02 |
Dnab Diagnostics Inc. |
Compositions and methods for determining the activity of DNA-binding proteins and of initiation of transcription
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
AU1013701A
(en)
|
1999-10-22 |
2001-05-08 |
Aventis Pasteur Limited |
Modified gp100 and uses thereof
|
JP2003512077A
(ja)
|
1999-10-26 |
2003-04-02 |
インターナショナル エイズ バクシーン イニシアティブ |
アルファウイルスレプリコンを発現する侵襲性細菌
|
EP2975127A1
(en)
|
1999-10-29 |
2016-01-20 |
GlaxoSmithKline Biologicals SA |
Neisserial antigenic peptides
|
DE60043197D1
(ja)
|
1999-11-18 |
2009-12-03 |
Univ Kyoto |
|
PT1248647E
(pt)
|
2000-01-17 |
2010-11-18 |
Novartis Vaccines & Diagnostics Srl |
Vacina de vesícula da membrana externa (omv) compreendendo proteínas de membrana externa de n. meningitidis do serogrupo b
|
WO2001066595A2
(en)
|
2000-03-08 |
2001-09-13 |
Chiron Corporation |
Human fgf-23 gene and gene expression products
|
EP1278542A2
(en)
|
2000-05-05 |
2003-01-29 |
Cytos Biotechnology AG |
Molecular antigen arrays and vaccines
|
ES2276788T3
(es)
|
2000-05-10 |
2007-07-01 |
Sanofi Pasteur Limited |
Polipeptidos inmunogenos codificados por minigenes mage y sus utilizaciones.
|
DE60135983D1
(de)
|
2000-05-31 |
2008-11-13 |
Novartis Vaccines & Diagnostic |
Verfahren zur reinigung von alphaviralen replikon partikeln
|
US6783939B2
(en)
|
2000-07-07 |
2004-08-31 |
Alphavax, Inc. |
Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
|
AU2001290642A1
(en)
*
|
2000-09-07 |
2002-03-22 |
University Of North Carolina At Chapel Hill |
Vectors derived from south african arbovirus no. 86
|
EP2189473A3
(en)
|
2000-10-27 |
2010-08-11 |
Novartis Vaccines and Diagnostics S.r.l. |
Nucleic and proteins from streptococcus groups A & B
|
ATE460472T1
(de)
|
2000-12-08 |
2010-03-15 |
Life Technologies Corp |
Verfahren und zusammensetzungen zur synthese von nukleinsäuremolekülen unter verwendung multipler erkennungsstellen
|
US7264810B2
(en)
|
2001-01-19 |
2007-09-04 |
Cytos Biotechnology Ag |
Molecular antigen array
|
US7094409B2
(en)
*
|
2001-01-19 |
2006-08-22 |
Cytos Biotechnology Ag |
Antigen arrays for treatment of allergic eosinophilic diseases
|
US7128911B2
(en)
*
|
2001-01-19 |
2006-10-31 |
Cytos Biotechnology Ag |
Antigen arrays for treatment of bone disease
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
CN1520303B
(zh)
*
|
2001-03-27 |
2013-04-24 |
纽约大学 |
利用基于α病毒且靶向高亲和性层粘连蛋白受体的载体进行肿瘤治疗
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
AU2002258728A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc-3 and diagnostic and therapeutic uses thereof
|
AU2002305151A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene scc-112 and diagnostic and therapeutic uses thereof
|
AU2002303261A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc2 and diagnostic and therapeutic uses thereof
|
CA2830887C
(en)
|
2001-06-05 |
2016-11-29 |
Curevac Gmbh |
Pharmaceutical composition containing a stabilised mrna optimised for translation in its coding regions
|
ATE437222T1
(de)
|
2001-09-06 |
2009-08-15 |
Alphavax Inc |
Alphavirus replikon-vektorsysteme
|
US7115266B2
(en)
*
|
2001-10-05 |
2006-10-03 |
Cytos Biotechnology Ag |
Angiotensin peptide-carrier conjugates and uses thereof
|
BR0213117A
(pt)
|
2001-10-05 |
2004-09-21 |
Cytos Biotechnology Ag |
Conjugados peptìdeo angiotensina-veìculo e seus usos
|
WO2003085087A2
(en)
|
2002-04-09 |
2003-10-16 |
Aventis Pasteur, Limited |
Modified cea nucleic acid and expression vectors
|
NZ546711A
(en)
|
2001-12-12 |
2008-06-30 |
Chiron Srl |
Immunisation against chlamydia trachomatis
|
US7877273B2
(en)
*
|
2002-01-08 |
2011-01-25 |
Fredric David Abramson |
System and method for evaluating and providing nutrigenomic data, information and advice
|
US20030219459A1
(en)
*
|
2002-01-18 |
2003-11-27 |
Cytos Biotechnology Ag |
Prion protein carrier-conjugates
|
EP1490395A4
(en)
|
2002-03-15 |
2006-06-21 |
Wyeth Corp |
MUTANTS OF NON-TYPABLE HAEMOPHILUS INFLUENZAE P4 PROTEIN WITH REDUCED ENZYMATIC ACTIVITY
|
US7244565B2
(en)
|
2002-04-10 |
2007-07-17 |
Georgetown University |
Gene shinc-3 and diagnostic and therapeutic uses thereof
|
US7138512B2
(en)
|
2002-04-10 |
2006-11-21 |
Georgetown University |
Gene SHINC-2 and diagnostic and therapeutic uses thereof
|
AU2003242742B2
(en)
*
|
2002-06-20 |
2009-04-30 |
Cytos Biotechnology Ag |
Packaged virus-like particles for use as adjuvants: method of preparation and use
|
EP2351770A1
(en)
|
2002-07-17 |
2011-08-03 |
Cytos Biotechnology AG |
Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
|
BR0312297A
(pt)
*
|
2002-07-18 |
2005-04-12 |
Cytos Biotechnology Ag |
Conjugados veìculos de hapteno e seu uso
|
AU2003250110C1
(en)
|
2002-07-19 |
2008-05-29 |
Novartis Ag |
Vaccine compositions containing amyloid beta1-6 antigen arrays
|
DE60332377D1
(de)
|
2002-10-21 |
2010-06-10 |
Eisai Inc |
Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden
|
EP1562982B1
(en)
|
2002-11-15 |
2010-05-05 |
Novartis Vaccines and Diagnostics S.r.l. |
Unexpected surface proteins in neisseria meningitidis
|
ES2552687T3
(es)
|
2002-12-13 |
2015-12-01 |
Alphavax, Inc. |
Partículas alfavíricas y métodos de preparación
|
DK1585812T3
(en)
|
2002-12-13 |
2017-04-10 |
Alphavax Inc |
MULTI-ANTI-ANTI-ANTI-VIRUS REPLICATE PARTICLES AND PROCEDURES
|
JP2006517790A
(ja)
*
|
2003-01-09 |
2006-08-03 |
インヴィトロジェン コーポレーション |
ポリペプチド−核酸複合体の細胞の送達および活性化
|
WO2004085660A2
(en)
*
|
2003-03-20 |
2004-10-07 |
Alphavax, Inc. |
Improved alphavirus replicons and helper constructs
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
EP1623229A2
(en)
*
|
2003-05-15 |
2006-02-08 |
Cytos Biotechnology AG |
Selection of b cells with specificity of interest: method of preparation and use
|
AU2004257214B2
(en)
|
2003-07-11 |
2010-04-22 |
Alphavax, Inc. |
Alphavirus-based cytomegalovirus vaccines
|
US7910093B2
(en)
|
2003-08-19 |
2011-03-22 |
New York University |
Method for detecting cancer cells and monitoring cancer therapy
|
JP4668919B2
(ja)
*
|
2003-10-08 |
2011-04-13 |
サノフィ パストゥール インコーポレイテッド |
修飾cea/b7ベクター
|
RU2006130006A
(ru)
*
|
2004-01-20 |
2008-02-27 |
Цитос Биотехнологи Аг (Ch) |
Конъюгаты грелин-носитель
|
DK1736541T3
(da)
|
2004-03-29 |
2013-05-06 |
Galpharma Co Ltd |
Nyt modificeret galectin 9-protein og anvendelse heraf
|
DE602005012382D1
(de)
|
2004-05-18 |
2009-03-05 |
Alphavax Inc |
Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren
|
ES2292271B1
(es)
*
|
2004-05-20 |
2009-02-16 |
Proyecto De Biomedicina Cima, S.L. |
Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
|
CN1960752A
(zh)
*
|
2004-06-02 |
2007-05-09 |
赛托斯生物技术公司 |
非人类tnf-肽的载体偶联物的医药用途
|
WO2005122675A2
(en)
*
|
2004-06-21 |
2005-12-29 |
Quattromed As |
Optimized recognition site of the alphavirus non-structural protease for tag removal and specific processing of recombinant proetins
|
CA2572921C
(en)
*
|
2004-07-09 |
2017-01-03 |
The University Of North Carolina At Chapel Hill |
Replication-competent and propagation-defective venezuelan equine encephalitis (vee) viral adjuvants
|
US7998733B2
(en)
|
2004-10-05 |
2011-08-16 |
Merial Limited |
Chimeric vectors
|
AU2006302794B2
(en)
*
|
2005-02-15 |
2011-08-04 |
Children's Hospital, Inc. |
New live virus vaccines
|
SI2567976T1
(sl)
|
2005-03-23 |
2017-11-30 |
Genmab A/S |
Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma
|
US7303898B2
(en)
*
|
2005-03-29 |
2007-12-04 |
New York University |
Defective sindbis viral vectors
|
DK2054431T3
(da)
|
2006-06-09 |
2012-01-02 |
Novartis Ag |
Konformere af bakterielle adhæsiner
|
WO2008033966A2
(en)
|
2006-09-12 |
2008-03-20 |
Alphavax, Inc. |
Alphavirus replicon particles matched to protein antigens as immunological adjuvants
|
ES2746960T3
(es)
|
2006-09-12 |
2020-03-09 |
Alphavax Inc |
Partículas de replicón de alfavirus que codifican IL-12 como adyuvantes inmunológicos
|
CA2668417A1
(en)
*
|
2006-11-03 |
2008-05-15 |
Alphavax, Inc. |
Alphavirus and alphavirus replicon particle formulations and methods
|
WO2008116116A2
(en)
|
2007-03-20 |
2008-09-25 |
Harold Brem |
Gm-csf cosmeceutical compositions and methods of use thereof
|
AU2008266807B2
(en)
|
2007-06-21 |
2012-08-16 |
Alphavax, Inc. |
Promoterless cassettes for expression of alphavirus structural proteins
|
DK2222697T3
(da)
|
2007-11-01 |
2013-03-11 |
Perseid Therapeutics Llc |
Immunsuppressive polypeptider og nukleinsyrer
|
EP2370584B1
(en)
|
2008-12-01 |
2014-11-05 |
Alphavax, Inc. |
Use of microRNAs to control virus helper nucleic acids
|
EP2416662B1
(en)
|
2009-04-08 |
2015-03-25 |
Alphavax, Inc. |
Alphavirus replicon particles expressing trp2
|
US8563261B2
(en)
|
2009-09-28 |
2013-10-22 |
The Trustees Of The University Of Pennsylvania |
Method of diagnosing and treating interstitial cystitis
|
EE05711B1
(et)
|
2009-10-07 |
2014-04-15 |
Tartu Ülikool |
Meetod ja kompositsioon konditsionaalselt letaalsete viirusmutantide loomiseks ja eukarootse raku elulisuse k?rvaldamiseks
|
WO2011064437A2
(es)
|
2009-11-26 |
2011-06-03 |
Proyecto De Biomedicina Cima, S.L. |
Vectores virales y procedimientos útiles en la preparación de gdnf
|
ES2625406T3
(es)
|
2010-03-25 |
2017-07-19 |
Oregon Health & Science University |
Glicoproteínas de CMV y vectores recombinantes
|
US9198975B2
(en)
|
2010-12-01 |
2015-12-01 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for targeting sites of neovascular growth
|
WO2012101509A2
(en)
|
2011-01-28 |
2012-08-02 |
Sanofi Pasteur Sa |
Immunological compositions against hiv
|
HUE037408T2
(hu)
|
2011-06-10 |
2018-08-28 |
Univ Oregon Health & Science |
CMV glikoproteinek és rekombináns vektorok
|
CA2789539A1
(en)
|
2011-09-12 |
2013-03-12 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
|
US9402894B2
(en)
|
2011-10-27 |
2016-08-02 |
International Aids Vaccine Initiative |
Viral particles derived from an enveloped virus
|
EP2679596B1
(en)
|
2012-06-27 |
2017-04-12 |
International Aids Vaccine Initiative |
HIV-1 env glycoprotein variant
|
WO2014140938A2
(en)
|
2013-03-14 |
2014-09-18 |
Centre Hospitalier Universitaire Vaudois |
Immunological methods
|
US20150065381A1
(en)
|
2013-09-05 |
2015-03-05 |
International Aids Vaccine Initiative |
Methods of identifying novel hiv-1 immunogens
|
US10058604B2
(en)
|
2013-10-07 |
2018-08-28 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
US10174292B2
(en)
|
2015-03-20 |
2019-01-08 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
EP3072901A1
(en)
|
2015-03-23 |
2016-09-28 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
US20190282679A1
(en)
|
2016-04-18 |
2019-09-19 |
Rima McLeod |
Toxoplasma gondii vaccines and their use
|
IL268856B1
(en)
*
|
2017-02-27 |
2024-05-01 |
Translate Bio Inc |
Methods for the purification of messenger RNA
|
WO2021030268A2
(en)
|
2019-08-09 |
2021-02-18 |
Nutcracker Therapeutics, Inc. |
Microfluidic apparatus and methods of use thereof
|